相关实验视频

Updated: Jul 1, 2026

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

基于粉的化纳米颗粒的开发,用于安福特里辛B的输送

Yonas Brhane¹, Anteneh Belete¹, Stefaan C De Smedt²

¹Department of Pharmaceutics and Industrial Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia; Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-AFRICA), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

International journal of pharmaceutics

|November 17, 2025

概括

研究人员开发了低成本,生物相容的粉纳米颗粒来输送安福特里辛B,为昂贵的脂质体配方提供了潜在的替代品. 这些新型纳米粒子显示了可比的药物释放和稳定性.

科学领域:

制药纳米技术制药纳米技术
药物输送系统药物输送系统
材料科学材料科学材料科学

背景情况:

氨酸B是一种重要的抗真菌药物,但其毒性和脂质体配方 (AmBisome®) 的高成本限制了其可获得性.
开发成本效益高,更安全的安二乙药物输送系统至关重要,特别是对于低收入和中等收入国家.

研究的目的:

开发一种新的,低成本的,生物相容的,稳定的基于粉的纳米载体,用于安福特里辛B的输送.
通过响应表面方法 (RSM) 和中央复合材料设计 (CCD) 来优化这些粉纳米颗粒的配方.

主要方法:

使用溶剂乳化扩散技术制备了化 Dioscorea abyssinica 粉纳米颗粒 (PDASNPs).
使用响应表面方法 (RSM) 和中央复合材料设计 (CCD) 来优化表面活性剂度,均质化速度和时间.
评估了粒子大小,多分散性指数 (PDI),泽塔潜力 (ζ),形态,体外释放和稳定性.

主要成果:

优化的PDASNP可以达到149nm的粒子大小,PDI为0.22,而zeta电位为-20mV.
在体外释放药物的AMPHOTERICIN B装载PDASNP的概况与AMBISOME®相似.
开发的纳米载体在4°C下至少3个月表现出稳定性.

结论:

化迪奥斯科雷亚亚亚比西尼卡粉纳米颗粒 (PDASNPs) 代表了一种有希望的,具有成本效益的纳米载体,用于安福特里辛B的输送.
这种配方提供了一个潜在的替代现有的脂肪体安二B,解决成本和可访问性障碍.

关键词:

氨基氨酸B (Amphotericin B) 是一种氨基氨酸.中心复合设计设计在体外释放的体外释放.纳米颗粒纳米颗粒基粉是一种基粉.响应表面的方法响应表面方法溶剂乳化扩散溶剂的扩散.

更多相关视频

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...